STM-05

STM-05 is a preclinical-stage secretome-based therapeutic candidate developed by Secretome Therapeutics for the treatment of Dilated Cardiomyopathy (DCM). The drug utilizes the "secretome"—a comprehensive collection of proteins, growth factors, and extracellular vesicles (exosomes) secreted by cells—to induce therapeutic effects through paracrine signaling. By delivering these bioactive factors, STM-05 aims to promote tissue repair, reduce fibrosis, and modulate inflammatory responses within the heart, addressing the underlying pathology of DCM where the heart's ventricles enlarge and weaken. It represents a cell-free approach to regenerative medicine, leveraging the benefits of stem cell signaling without the complexities of live cell transplantation.